Posted by Michael Wonder on 25 Feb 2019
Health Canada approves Otsuka and Lundbeck's Rexulti (brexpiprazole) as adjunctive treatment of major depressive disorder
22 February 2019 - Otsuka and Lundbeck announce that Health Canada issued a Notice of Compliance for Rexulti (brexpiprazole) for use as an adjunct to antidepressants for the treatment of major depressive disorder in adult patients with an inadequate response to prior anti-depressant treatments during the current episode.
Rexulti (brexpiprazole) was discovered by Otsuka and co-developed by Otsuka and Lundbeck. It is co-marketed by the two companies.
Rexulti was approved by Health Canada for the treatment of schizophrenia in adults in February 2017.
